Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study

Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study

Abstract Objective The prognosis of patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) is poor. Although patients who fail first‐line salvage chemotherapy are candidates for second‐line salvage chemotherapy, the optimal treatment strategy for these patients has not yet...

Full description

Bibliographic Details
Main Authors: Yu Yagi, Yusuke Kanemasa, Yuki Sasaki, Mina Sei, Takuma Matsuo, Kento Ishimine, Yudai Hayashi, Mano Mino, An Ohigashi, Yuka Morita, Taichi Tamura, Shohei Nakamura, Toshihiro Okuya, Takuya Shimizuguchi, Naoki Shingai, Takashi Toya, Hiroaki Shimizu, Yuho Najima, Takeshi Kobayashi, Kyoko Haraguchi, Noriko Doki, Yoshiki Okuyama, Tatsu Shimoyama
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Cancer Medicine
Subjects:
autologous stem cell transplantation
chimeric antigen receptor T‐cell therapy
relapsed or refractory diffuse large B‐cell lymphoma
salvage chemotherapy
Online Access:https://doi.org/10.1002/cam4.6412

Internet

https://doi.org/10.1002/cam4.6412

Similar Items